Abstract Details

Title Characterizing the Swallow Tail Sign: A Cross-Sectional Clinicopathologic Analysis of the Pattern of Brain Atrophy in Autopsy-Confirmed Lewy Body Dementia

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 3-015

Objective OBJECTIVE: To describe a novel radiographic sign found in Lewy body dementia, which can be used to aid in diagnosis.

Background BACKGROUND: There is a dearth of guidelines for diagnosing Lewy body dementia using radiologic biomarkers. At present, guidance from the literature notes that central atrophy can occur in this disease process. We aim to clarify specific brain areas affected by atrophy. In the future, qualitative and volumetric measurements targeting these areas may be used in memory disorder evaluations.

Design/Methods DESIGN/METHODS: A retrospective review was conducted of clinicopathological data from participants who donated their brains to the Biggs Institute’s Brain Donation program. Thirty patients with predominantly diffuse neocortical Lewy body dementia and available antemortem brain imaging were included in the analysis.

Results RESULTS: Preliminary data indicate that patients with autopsy-confirmed predominant diffuse neocortical Lewy body dementia had several characteristic radiologic findings. The majority of patients have deep parieto-occipital atrophy which we describe as the “Swallow Tail sign.” In addition, patients often had medial frontal, anterior temporal, and midbrain atrophy.

Conclusions

CONCLUSIONS: The pattern of brain atrophy described in this clinicopathological study, including the “Swallow Tail sign”, can be employed as a radiologic biomarker of Lewy body dementia.

Authors/Disclosures
Preston A. Roche, MD PRESENTER	Dr. Roche has nothing to disclose.
A. Campbell Sullivan	Dr. Sullivan has received personal compensation for serving as an employee of UT Health San Antonio. The institution of Dr. Sullivan has received research support from Baptist Health Foundation. The institution of Dr. Sullivan has received research support from NIH.
Rima M. Chaudhari, MD	Dr. Chaudhari has nothing to disclose.
Arash Salardini, MBBS (UTHSCA)	Dr. Salardini has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. The institution of Dr. Salardini has received research support from NIH/NIA. The institution of Dr. Salardini has received research support from Taylor Family. Dr. Salardini has received publishing royalties from a publication relating to health care.
Kevin F. Bieniek, PhD	Dr. Bieniek has nothing to disclose.
Margaret Flanagan, MD	Dr. Flanagan has nothing to disclose.
Alicia S. Parker, MD (UT Health San Antonio)	An immediate family member of Dr. Parker has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Sanara Med Tech. An immediate family member of Dr. Parker has stock in Sanara Med Tech. An immediate family member of Dr. Parker has stock in Rochal Industries. An immediate family member of Dr. Parker has stock in Rochal Parnters. The institution of Dr. Parker has received research support from Texas Alzheimer's Research and Care Consortium. The institution of an immediate family member of Dr. Parker has received research support from Rochal Industries. An immediate family member of Dr. Parker has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��